{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 437135864
| IUPAC_name = 2,2-dimethylpropanoyloxymethyl (2''S'',5''R'',6''R'')-6-[(azepan-1-ylmethylene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
| image = Pivmecillinam.svg
| image2 = Pivmecillinam-3D-balls.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|pivmecillinam}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category = <br/>Appears safe in pregnancy<ref name=Nicolle/>
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = Low
| protein_bound = 5 to 10% (as mecillinam)
| metabolism = Pivmecillinam is [[hydrolysis|hydrolyzed]] to mecillinam
| elimination_half-life = 1 to 3 hours
| excretion = [[Kidney|Renal]] and biliary, mostly as mecillinam
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 32886-97-8
| CAS_supplemental =  
| ATC_prefix = J01
| ATC_suffix = CA08
| ATC_supplemental =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1650818
| PubChem = 36272
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 33356
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1WAM1OQ30B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02889
<!--Chemical data-->
| C=21 | H=33 | N=3 | O=5 | S=1
| molecular_weight = 439.569 g/mol
| smiles = CC1(C(N2C(S1)C(C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C
}}

'''Pivmecillinam''' ([[International Nonproprietary Name|INN]]) or '''amdinocillin pivoxil''' ([[United States Approved Name|USAN]], trade names '''Selexid''', '''Penomax''' and '''Coactabs''') is an orally active [[prodrug]] of [[mecillinam]], an extended-spectrum [[penicillin]] [[antibiotic]]. Pivmecillinam is the [[pivaloyloxymethyl]] [[carboxylate ester|ester]] of mecillinam. Neither drug is available in the United States.<ref name=POC-IT>{{cite web |url=http://prod.hopkins-abxguide.org/antibiotics/antibacterial/pcn_others/amdinocillin__mecillinam_.html |title=Amdinocillin (Mecillinam) |vauthors=Pham P, Bartlett JG |date=August 28, 2008 |work=Point-of-Care Information Technology ABX Guide |publisher=[[Johns Hopkins University]]}} Retrieved on August 31, 2008. Freely available with registration.</ref>

Pivmecillinam is only considered to be active against [[Gram-negative bacteria]], and is used primarily in the treatment of lower [[urinary tract infection]]s. In the [[Nordic countries]], it has been widely used in that indication since the 1970s. It has been proposed as the [[first-line treatment|first-line drug]] of choice for [[empirical treatment]] of acute [[cystitis]].<ref name=Nicolle>{{cite journal |author=Nicolle LE |title=Pivmecillinam in the treatment of urinary tract infections |journal=J Antimicrob Chemother |volume=46  |issue= Suppl A|pages=35–39 |date=August 2000 |pmid=10969050 |doi= 10.1093/jac/46.suppl_1.35|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=10969050}}</ref><ref>{{cite journal |author=Graninger W |title=Pivmecillinam—therapy of choice for urinary tract infection |journal=Int J Antimicrob Agents |volume=Suppl 2 |issue= |pages=73–8 |series=22 |date=October 2003 |pmid=14527775 |doi= 10.1016/S0924-8579(03)00235-8|url=http://linkinghub.elsevier.com/retrieve/pii/S0924857903002358}}</ref> It has also been used to treat [[paratyphoid fever]] and shigellosis.<ref>{{cite journal |vauthors=Tanphaichitra D, Srimuang S, Chiaprasittigul P, Menday P, Christensen OE |title=The combination of pivmecillinam and pivampicillin in the treatment of enteric fever |journal=Infection |volume=12 |issue=6 |pages=381–3 |year=1984 |pmid=6569851 |doi= 10.1007/BF01645219|url=}}</ref>

==Activity==
{{See also|Mecillinam}}

==Adverse effects==
{{see also|Beta-lactam antibiotic#Adverse effects|l1=Beta-lactam antibiotic: Adverse effects}}
The [[adverse drug reaction|adverse effect]] profile of pivmecillinam is similar to that of other penicillins. The most common side effects of mecillinam use are [[rash]] and gastrointestinal upset, including [[nausea]] and [[vomiting]].<ref name=Nicolle/><ref name=eMC>{{cite web |url=http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=2566 |title=Selexid Tablets |date=June 5, 2008 |publisher=electronic Medicines Compendium}} Retrieved on August 31, 2008.</ref>

Prodrugs that release [[pivalic acid]] when broken down by the body — such as pivmecillinam, [[pivampicillin]] and [[cefditoren pivoxil]] — have long been known to deplete levels of [[carnitine]].<ref>{{cite journal  |vauthors=Holme E, Greter J, Jacobson CE, etal |title=Carnitine deficiency induced by pivampicillin and pivmecillinam therapy |journal=Lancet |volume=2 |issue=8661 |pages=469–73 |date=August 1989 |pmid=2570185 |doi= 10.1016/S0140-6736(89)92086-2|url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(89)92086-2}}</ref><ref name=Brass>{{cite journal |author=Brass EP |title=Pivalate-generating prodrugs and carnitine homeostasis in man |journal=Pharmacol Rev |volume=54 |issue=4 |pages=589–98 |date=December 2002 |pmid=12429869 |doi= 10.1124/pr.54.4.589|url=http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12429869}}</ref> This is not due to the drug itself, but to pivalate, which is mostly removed from the body by forming a conjugate with carnitine. Although short-term use of these drugs can cause a marked decrease in blood levels of carnitine,<ref>{{cite journal |vauthors=Abrahamsson K, Holme E, Jodal U, Lindstedt S, Nordin I |title=Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration—a risk irrespective of age |journal=Biochem. Mol. Med. |volume=55 |issue=1 |pages=77–9 |date=June 1995 |pmid=7551831 |doi= 10.1006/bmme.1995.1036|url=http://linkinghub.elsevier.com/retrieve/pii/S1077315085710368}}</ref> it is unlikely to be of clinical significance;<ref name=Brass/> long-term use, however, appears problematic and is not recommended.<ref name=Brass/><ref>{{cite journal |vauthors=Holme E, Jodal U, Linstedt S, Nordin I |title=Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children |journal=Scand J Clin Lab Invest |volume=52 |issue=5 |pages=361–72 |date=September 1992 |pmid=1514015 |doi= 10.3109/00365519209088371|url=}}</ref><ref>{{cite journal |vauthors=Makino Y, Sugiura T, Ito T, Sugiyama N, Koyama N |title=Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid |journal=Pediatrics |volume=120 |issue=3 |pages=e739–41 |date=September 2007 |pmid=17724113 |doi=10.1542/peds.2007-0339}}</ref>

==References==
{{Reflist}}

[[Image:Mecillinam.svg|thumb|270px|[[Skeletal formula]] of mecillinam, the active moiety of pivmecillinam]]<!--width parameter used so image will align with Drugbox-->

{{Beta-lactam antibiotics}}

[[Category:Penicillins]]
[[Category:Azepanes]]
[[Category:Prodrugs]]